{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:27:44Z","timestamp":1793039264477,"version":"4.5.0"},"reference-count":54,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>\n                    The metabolic syndrome (MetS) concept gathers in a single entity a set of metabolic abnormalities that have in common a close relationship with ectopic deposit of lipids, insulin resistance, and chronic low-grade inflammation. It is a valuable teaching tool to help health professionals to understand and integrate the consequences of lipotoxicity and the adverse metabolic consequences of insulin resistance. Also, it is useful to identify subjects with a high risk for having incident type 2 diabetes. Systems biology studies have gained a prominent role in understanding the interaction between adipose tissue dysfunction, insulin action, and the MetS traits and co-morbidities (that is, non-alcoholic steatohepatitis, or NASH). This approach may allow the identification of new therapeutic targets (that is,\n                    <ns4:italic>de novo<\/ns4:italic>\n                    lipogenesis inhibitors for NASH). Treatment targets on MetS are the adoption of a healthy lifestyle, weight loss, and the control of the co-morbidities (hyperglycemia, dyslipidemia, arterial hypertension, among others). The long-term goals are the prevention of type 2 diabetes, cardiovascular events, and other MetS-related outcomes. In the last few decades, new drugs derived from the identification of innovative treatment targets have come on the market. These drugs have positive effects on more than one MetS component (that is, hyperglycemia and weight control). New potential treatment targets are under study.\n                  <\/ns4:p>","DOI":"10.12688\/f1000research.17122.1","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T13:47:31Z","timestamp":1554299251000},"page":"370","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":69,"title":["Recent advances in managing\/understanding the metabolic syndrome"],"prefix":"10.12688","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-0241","authenticated-orcid":false,"given":"Carlos A.","family":"Aguilar-Salinas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannia","family":"Viveros-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"1-12","DOI":"10.1111\/obr.12229","article-title":"Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies.","volume":"16","author":"S O'Neill","year":"2015","journal-title":"Obes Rev."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"17-24","DOI":"10.1016\/j.diabres.2018.07.021","article-title":"Abdominal obesity phenotypes and incident diabetes over 12 years of follow-up: The Tehran Lipid and glucose study.","volume":"144","author":"F Salehinia","year":"2018","journal-title":"Diabetes Res Clin Pract."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"13-8","DOI":"10.1016\/j.ijcard.2018.05.080","article-title":"Patterns of clustering of the metabolic syndrome components and its association with coronary heart disease in the Multi-Ethnic Study of Atherosclerosis (MESA): A latent class analysis.","volume":"271","author":"S Riahi","year":"2018","journal-title":"Int J Cardiol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"456-63","DOI":"10.1001\/jamaneurol.2015.4899","article-title":"Metabolic Syndrome and the Risk of Mild Cognitive Impairment and Progression to Dementia: Follow-up of the Singapore Longitudinal Ageing Study Cohort.","volume":"73","author":"T Ng","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1741-7015-9-48","article-title":"Metabolic syndrome: definitions and controversies.","volume":"9","author":"E Kassi","year":"2011","journal-title":"BMC Med."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"109-29","DOI":"10.1016\/j.pop.2017.10.003","article-title":"Metabolic Syndrome: Systems Thinking in Heart Disease.","volume":"45","author":"R Dommermuth","year":"2018","journal-title":"Prim Care."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"223-31","DOI":"10.1016\/j.arcmed.2004.12.003","article-title":"The Metabolic Syndrome: A Concept Hard to Define.","volume":"36","author":"C Aguilar","year":"2005","journal-title":"Arch Med Res."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"469-80","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.","volume":"23","author":"P Alberti KG, Zimmet","year":"2006","journal-title":"Diabet Med."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"539-53","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO Consultation.","volume":"15","author":"P Alberti KG, Zimmet","year":"1998","journal-title":"Diabet Med."},{"key":"ref-10","first-page":"442-3","article-title":"Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR).","volume":"16","author":"B Balkau","year":"1999","journal-title":"Diabet Med."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"2486-97","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).","volume":"285","year":"2001","journal-title":"JAMA."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"237-52","DOI":"10.4158\/EP.9.S2.5","article-title":"American College of Endocrinology position statement on the insulin resistance syndrome.","volume":"9","author":"D Einhorn","year":"2003","journal-title":"Endocr Pract."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"2735-52","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: An American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement.","volume":"112","author":"S Grundy","year":"2005","journal-title":"Circulation."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"49-63","DOI":"10.1016\/j.mcna.2017.08.006","article-title":"Guideline Recommendations for Obesity Management.","volume":"102","author":"D Ryan","year":"2018","journal-title":"Med Clin North Am."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"2420-6","DOI":"10.2337\/dc06-0611","article-title":"Design and validation of a population-based definition of the metabolic syndrome.","volume":"29","author":"C Aguilar-Salinas","year":"2006","journal-title":"Diabetes Care."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"e009754","DOI":"10.1161\/JAHA.118.009754","article-title":"Assessing Baseline and Temporal Changes in Cardiometabolic Risk Using Metabolic Syndrome Severity and Common Risk Scores.","volume":"7","author":"M Gurka","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"2421-30","DOI":"10.2337\/dc18-1079","article-title":"Use of a Metabolic Syndrome Severity Z Score to Track Risk During Treatment of Prediabetes: An Analysis of the Diabetes Prevention Program.","volume":"41","author":"M DeBoer","year":"2018","journal-title":"Diabetes Care."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"97-103.e1\u20133","DOI":"10.1016\/j.jpeds.2015.10.093","article-title":"Continuous and Dichotomous Metabolic Syndrome Definitions in Youth Predict Adult Type 2 Diabetes and Carotid Artery Intima Media Thickness: The Cardiovascular Risk in Young Finns Study.","volume":"171","author":"C Magnussen","year":"2016","journal-title":"J Pediatr."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.2337\/dc06-1341","article-title":"A continuous metabolic syndrome risk score: utility for epidemiological analyses.","volume":"29","author":"K Wijndaele","year":"2006","journal-title":"Diabetes Care."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"19-25","DOI":"10.1159\/000441851","article-title":"Utility of Continuous Metabolic Syndrome Score in Assessing Risk of Type 2 Diabetes: The Isfahan Diabetes Prevention Study.","volume":"68","author":"M Janghorbani","year":"2016","journal-title":"Ann Nutr Metab."},{"key":"ref-21","first-page":"88-96","article-title":"Continuous metabolic syndrome risk score for predicting cardiovascular disease in the Chinese population.","volume":"21","author":"G Kang","year":"2012","journal-title":"Asia Pac J Clin Nutr."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"2156-64","DOI":"10.1161\/CIRCULATIONAHA.111.028381","article-title":"Food and Drug Administration's Obesity Drug Guidance Document: a short history.","volume":"125","author":"E Colman","year":"2012","journal-title":"Circulation."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"558-566","DOI":"10.1007\/s00125-018-4787-8","article-title":"Metabolic health in normal-weight and obese individuals.","volume":"62","author":"M Schulze","year":"2019","journal-title":"Diabetologia."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"219-27","DOI":"10.1007\/s11154-013-9252-x","article-title":"Metabolically healthy obesity: definitions, determinants and clinical implications.","volume":"14","author":"C Phillips","year":"2013","journal-title":"Rev Endocr Metab Disord."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"161-96","DOI":"10.1007\/978-3-319-48382-5_7","article-title":"Adipose Tissue Function and Expandability as Determinants of Lipotoxicity and the Metabolic Syndrome.","volume":"960","author":"S Carobbio","year":"2017","journal-title":"Adv Exp Med Biol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"572-9","DOI":"10.1016\/j.cmet.2017.02.002","article-title":"Systems Biology of Metabolism: A Driver for Developing Personalized and Precision Medicine.","volume":"25","author":"J Nielsen","year":"2017","journal-title":"Cell Metab."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"14200","DOI":"10.1038\/s41598-018-31865-w","article-title":"Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome.","volume":"8","author":"A Lovric","year":"2018","journal-title":"Sci Rep."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"263-72","DOI":"10.1016\/j.ymben.2019.01.001","article-title":"Pyruvate kinase L\/R is a regulator of lipid metabolism and mitochondrial function.","volume":"52","author":"Z Liu","year":"2019","journal-title":"Metab Eng."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"74-82","DOI":"10.1172\/JCI88883","article-title":"The ominous triad of adipose tissue dysfunction: Inflammation, fibrosis, and impaired angiogenesis.","volume":"127","author":"C Crewe","year":"2017","journal-title":"J Clin Invest."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"257-80","DOI":"10.1016\/j.trsl.2015.06.017","article-title":"Targeting inflammation in metabolic syndrome.","volume":"167","author":"F Welty","year":"2016","journal-title":"Transl Res."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"15-28","DOI":"10.1038\/nrendo.2015.189","article-title":"Regulation of metabolism by the innate immune system.","volume":"12","author":"D Lackey","year":"2016","journal-title":"Nat Rev Endocrinol."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"572-87","DOI":"10.1038\/nrendo.2017.80","article-title":"Regulation of hepatic glucose metabolism in health and disease.","volume":"13","author":"M Petersen","year":"2017","journal-title":"Nat Rev Endocrinol."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"12-22","DOI":"10.1172\/JCI77812","article-title":"The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux.","volume":"126","author":"V Samuel","year":"2016","journal-title":"J Clin Invest."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"795-803","DOI":"10.1016\/j.molmet.2016.07.004","article-title":"Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome.","volume":"5","author":"S Ussar","year":"2016","journal-title":"Mol Metab."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1061-75","DOI":"10.2741\/4441","article-title":"Childhood obesity: a systems medicine approach.","volume":"21","author":"W Stone","year":"2016","journal-title":"Front Biosci (Landmark Ed)."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1603-14","DOI":"10.1042\/CS20160005","article-title":"Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance?","volume":"130","author":"M Bl\u00fcher","year":"2016","journal-title":"Clin Sci (Lond)."},{"key":"ref-37","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2016-0051","article-title":"Browning of white adipose tissue: lessons from experimental models.","volume":"31","author":"T Bargut","year":"2017","journal-title":"Horm Mol Biol Clin Investig."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"364-73","DOI":"10.1016\/j.tcm.2015.10.004","article-title":"Metabolic syndrome update.","volume":"26","author":"S Grundy","year":"2016","journal-title":"Trends Cardiovasc Med."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"e821-e841","DOI":"10.1161\/CIR.0000000000000563","article-title":"Medical Nutrition Education, Training, and Competencies to Advance Guideline-Based Diet Counseling by Physicians: A Science Advisory From the American Heart Association.","volume":"137","author":"K Aspry","year":"2018","journal-title":"Circulation."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1745-6215-12-107","article-title":"The Reversal Intervention for Metabolic Syndrome (TRIMS) study: rationale, design, and baseline data.","volume":"12","author":"A Dunkley","year":"2011","journal-title":"Trials."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"922-33","DOI":"10.2337\/dc13-2195","article-title":"Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis.","volume":"37","author":"A Dunkley","year":"2014","journal-title":"Diabetes Care."},{"key":"ref-42","doi-asserted-by":"publisher","DOI":"10.3390\/nu9080913","article-title":"Precision Nutrition: A Review of Personalized Nutritional Approaches for the Prevention and Management of Metabolic Syndrome.","volume":"9","author":"J de Toro-Mart\u00edn","year":"2017","journal-title":"Nutrients."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"152-64","DOI":"10.1016\/S2213-8587(13)70218-3","article-title":"Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery.","volume":"2","author":"S Madsbad","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"716-26","DOI":"10.1001\/jamasurg.2014.514","article-title":"Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial.","volume":"149","author":"F Halperin","year":"2014","journal-title":"JAMA Surg."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"105-13","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.","volume":"6","author":"M Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"444-452","DOI":"10.1111\/dme.13898","article-title":"Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.","volume":"36","author":"H Hussein","year":"2019","journal-title":"Diabet Med."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"1720-8","DOI":"10.2337\/dbi17-0007","article-title":"Targeting FXR and FGF19 to Treat Metabolic Diseases-Lessons Learned From Bariatric Surgery.","volume":"67","author":"N Bozadjieva","year":"2018","journal-title":"Diabetes."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"121-31","DOI":"10.1007\/s12291-017-0668-z","article-title":"A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?","volume":"33","author":"G Chikara","year":"2018","journal-title":"Indian J Clin Biochem."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"267-76","DOI":"10.1016\/j.ejmech.2018.09.071","article-title":"Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPAR\u03b3 and PPAR\u03b4.","volume":"159","author":"Z Li","year":"2018","journal-title":"Eur J Med Chem."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"343-352.e2","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The Sustained Effects of a Dual GIP\/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.","volume":"26","author":"J Frias","year":"2017","journal-title":"Cell Metab."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"333-9","DOI":"10.1080\/17446651.2018.1537779","article-title":"Sotagliflozin: a combined SGLT1\/SGLT2 inhibitor to treat diabetes.","volume":"13","author":"M Rendell","year":"2018","journal-title":"Expert Rev Endocrinol Metab."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"457-61","DOI":"10.1021\/acsmedchemlett.8b00073","article-title":"Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes.","volume":"9","author":"S Neelamkavil","year":"2018","journal-title":"ACS Med Chem Lett."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"2213-21","DOI":"10.2147\/DDDT.S170518","article-title":"Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis.","volume":"12","author":"Y Hu","year":"2018","journal-title":"Drug Des Devel Ther."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12876-017-0736-0","article-title":"Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.","volume":"18","author":"R Tiessen","year":"2018","journal-title":"BMC Gastroenterol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-370\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-370\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-370\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T13:54:41Z","timestamp":1554299681000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-370\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":54,"URL":"https:\/\/doi.org\/10.12688\/f1000research.17122.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.18720.r46720","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.18720.r46722","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.18720.r46721","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-370\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.18720.r46720, Christopher Byrne, Endocrinology and Metabolism Unit, Southampton General Hospital, University of Southampton, Southampton, SO16 6YD, UK, 03 Apr 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-370\/v1#referee-response-46720","order":0,"name":"referee-response-46720","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.18720.r46721, Neil Stone, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, 03 Apr 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-370\/v1#referee-response-46721","order":1,"name":"referee-response-46721","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.18720.r46722, Jorge Calles-Escandon, Section on Endocrinology, MetroHealth Regional, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA, 03 Apr 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-370\/v1#referee-response-46722","order":2,"name":"referee-response-46722","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}